<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554773</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AT3SC-002</org_study_id>
    <nct_id>NCT02554773</nct_id>
  </id_info>
  <brief_title>An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B</brief_title>
  <official_title>An Open-label Extension Study of Subcutaneously Administered ALN-AT3SC in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With ALN-AT3SC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and tolerability of ALN-AT3SC
      in male patients with moderate or severe hemophilia A or B.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The long-term safety and tolerability of ALN-AT3SC evaluated by the proportion of patients experiencing adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation</measure>
    <time_frame>Through day 811</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Bleeding Events</measure>
    <time_frame>Through day 811</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Amount of Factor VIII (FVIII) or Factor IX (FIX) Administered for the Treatment of Bleeding Episodes (FVIII) or factor IX (FIX) and ALN-AT3SC for treatment of bleeding episodes</measure>
    <time_frame>Through day 811</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events in Patients Receiving Concomitantly Administered Factor VIII (FVIII) or Factor IX (FIX) and ALN-AT3SC</measure>
    <time_frame>Through day 811</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of changes in health-related quality of life (QOL) with long-term dosing of ALN-AT3SC</measure>
    <time_frame>Through day 751</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-AT3SC</measure>
    <time_frame>Through day 362</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-AT3SC</measure>
    <time_frame>Through day 362</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-AT3SC</measure>
    <time_frame>Through day 362</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-AT3SC</measure>
    <time_frame>Through day 362</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-AT3SC</measure>
    <time_frame>Through day 362</time_frame>
    <description>CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of ALN-AT3SC</measure>
    <time_frame>Through day 362</time_frame>
    <description>V/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ALN-AT3SC on plasma levels of antithrombin (AT) and thrombin generation (TG)</measure>
    <time_frame>Through day 811</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>ALN-AT3SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-AT3SC</intervention_name>
    <description>Multiple doses of ALN-AT3SC by subcutaneous (sc) injection</description>
    <arm_group_label>ALN-AT3SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed and tolerated study drug dosing in study ALN-AT3SC-001

          -  Male aged ≥18 years

          -  Moderate or severe, clinically stable hemophilia A or B

          -  Agree to use 1 effective method of contraception throughout study participation and
             until 1 month after administration of the last dose of study drug

          -  Willing and able to comply with the study requirements and provide written informed
             consent

        Exclusion Criteria:

          -  Clinically significant liver disease

          -  Patients known to be human immunodeficiency virus seropositive and have a CD4 count
             &lt;200 cells/μL

          -  History of venous thromboembolism

          -  Current serious mental illness that, in the judgment of the Investigator, may
             compromise patient safety, ability to participate in all study assessments, or study
             integrity

          -  Clinically relevant history or presence of cardiovascular, respiratory,
             gastrointestinal, renal, neurological, inflammatory, or other diseases that, in the
             judgment of the Investigator, precludes study participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Madigan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Russian Federation</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>RNAi therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

